Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
Part of paid clinical trials in Camden, New Jersey.
- Sponsor
- The Cooper Health System
- Study ID
- NCT05203328
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Vapotherm — DEVICEMonitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
- Regular nasal canula — DEVICEMonitored anesthesia care with oxygen supplementation through a regular nasal cannula
Study Details
Our objective is to assess whether the use of high flow nasal cannula (Vapotherm, Exeter, NH) with monitored anesthesia care (MAC) during an endobronchial ultrasound (EBUS) bronchoscopy procedure will lead to less procedure interruptions, less hypoxic episodes, shorter duration of hypoxic episodes and shorter procedural durations when compared to regular MAC using a regular nasal canula.
Key Dates
- Start date
- Feb 1, 2022
- Status verified
- Sep 2025
- Primary completion
- Mar 31, 2026
- Completion
- May 31, 2026
Study Design
- Enrollment
- 198 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: High flow nasal cannula oxygenHigh flow nasal cannula oxygen will be provided during the procedure using a Vapotherm device
- Active Comparator: Regular nasal cannulaRegular nasal cannula oxygen will be provided during the procedure
Primary Outcome Measure
Number of interruption during EBUS procedure for hypoxia [ Time Frame: 1 day ]
Central Contacts
- Wissam Abouzgheib, MD(800) 826-6737
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cooper University Hospital | Camden | New Jersey | 08103 | Christopher Ambrogi, DO Wissam Abouzgheib, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Camden, NJ
By condition
By specialty
By research site
Related Studies
- Collection of Sputum and Labeling for Lung CancerRecruiting · bioAffinity Technologies Inc. · Summit, New Jersey
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- ATATcH Alternating Treatment Plans for Advanced CancerPHASE2 · Recruiting · Rutgers, The State University of New Jersey · Elizabeth, New Jersey